palinurin: an NSAID with antibacterial activity; isolated from Ircinia species; structure in firs t source
ID Source | ID |
---|---|
PubMed CID | 54726684 |
CHEMBL ID | 464381 |
MeSH ID | M0537966 |
Synonym |
---|
CHEMBL464381 |
palinurin |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Cyclin-dependent kinase 1 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0004 | 1.3452 | 10.0000 | AID722956 |
Casein kinase II subunit alpha' | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0003 | 1.4320 | 10.0000 | AID722949 |
Glycogen synthase kinase-3 alpha | Homo sapiens (human) | IC50 (µMol) | 1.6109 | 0.0010 | 1.2249 | 9.1000 | AID722958 |
Glycogen synthase kinase-3 beta | Homo sapiens (human) | IC50 (µMol) | 2.9960 | 0.0006 | 0.8013 | 10.0000 | AID718830; AID722955; AID729991 |
Casein kinase II subunit beta | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0003 | 1.4875 | 10.0000 | AID722949 |
Casein kinase II subunit alpha | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0005 | 1.3332 | 10.0000 | AID722949 |
Cyclin-dependent-like kinase 5 | Homo sapiens (human) | IC50 (µMol) | 25.0595 | 0.0002 | 1.1832 | 10.0000 | AID722957 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID722947 | Selectivity ratio of IC50 for human recombinant CDK1 to IC50 for human recombinant GSK3alpha | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722944 | Selectivity ratio of IC50 for human recombinant CDK5 to IC50 for human recombinant GSK3beta | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722954 | Inhibition of GSK-3beta in human SH-SY5Y cells assessed as reduction of tau phosphorylation at 15 to 200 uM after 18 hrs by ELISA sandwich method | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722955 | Inhibition of human recombinant GSK-3beta using GS2 peptide as substrate and [gamma33P]-ATP after 30 mins by scintillation counting | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722948 | Selectivity ratio of IC50 for human recombinant CDK5 to IC50 for human recombinant GSK3alpha | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722957 | Inhibition of human recombinant CDK5 using histone H1 as substrate and [gamma33P]-ATP after 20 mins by scintillation counting | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722951 | Non-competitive inhibition of human recombinant GSK-3beta using fixed concentration of [gamma33P]-ATP and GS2 peptide as substrate by double reciprocal plot analysis | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722952 | Non-competitive inhibition of human recombinant GSK-3beta using [gamma33P]-ATP and fixed concentration of GS2 peptide as substrate by double reciprocal plot analysis | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722958 | Inhibition of human recombinant GSK-3alpha using GS2 peptide as substrate and [gamma33P]-ATP after 12 mins by scintillation counting | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID729991 | Inhibition of GSK3beta (unknown origin) | 2013 | European journal of medicinal chemistry, Mar, Volume: 61 | Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β). |
AID722941 | Selectivity ratio of IC50 for human recombinant CK2 to IC50 for human recombinant GSK3beta | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID403324 | Cytotoxicity against human SK-MEL-2 cells | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Cytotoxic furanosesterterpenes from a marine sponge Psammocinia sp. |
AID722956 | Inhibition of human recombinant CDK1 using histone H1 as substrate and [gamma33P]-ATP after 15 mins by scintillation counting | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722942 | Selectivity ratio of IC50 for human recombinant MAPK to IC50 for human recombinant GSK3beta | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722949 | Inhibition of human recombinant CK2 using GS2 peptide as substrate and [gamma33P]-ATP after 30 mins by scintillation counting | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722943 | Selectivity ratio of IC50 for human recombinant CDK1 to IC50 for human recombinant GSK3beta | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722950 | Inhibition of human recombinant MAPK using myelin binding protein as substrate and [gamma33P]-ATP after 15 mins by scintillation counting | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID403323 | Cytotoxicity against human SKOV3 cells | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Cytotoxic furanosesterterpenes from a marine sponge Psammocinia sp. |
AID718830 | Non-ATP competitive inhibition of GSK3beta | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening. |
AID403322 | Cytotoxicity against human A549 cells | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Cytotoxic furanosesterterpenes from a marine sponge Psammocinia sp. |
AID722946 | Selectivity ratio of IC50 for human recombinant CK2 to IC50 for human recombinant GSK3alpha | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID403326 | Cytotoxicity against human HCT15 cells | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Cytotoxic furanosesterterpenes from a marine sponge Psammocinia sp. |
AID403325 | Cytotoxicity against human XF498 cells | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Cytotoxic furanosesterterpenes from a marine sponge Psammocinia sp. |
AID722953 | Cytotoxicity against human SH-SY5Y cells assessed as intracellular LDH level after 18 hrs | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
AID722945 | Selectivity ratio of IC50 for human recombinant MAPK to IC50 for human recombinant GSK3alpha | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.79) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |